[Biosimilars in Gastroenterology - how much uncertainly is ethically acceptable?]
Biosimilars use raises uncertainties with regards to efficacy despite potentially significant cost reductions. This requires a classical harm-benefit analysis. Important stakeholders include physicians and patients, companies producing biologica (drugs containing biotechnology-derived proteins as active substance), and companies producing biosimilars, as well as health insurance companies and politicians. They all have their distinct interests. In a rule-setting process, transparency is needed to protect the trust between patients and physicians. In an ideal world, the price of biologica without patent protection would be negotiated in a way that makes biosimilars unnecessary.
N
N
Knoepffler
D059451:Biosimilar Pharmaceuticals / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis / Q000191:economics* / Q000941:ethics*; D005762:Gastroenterology / Q000191:economics* / Q000941:ethics*; D005858:Germany; D017063:Outcome Assessment, Health Care / Q000941:ethics*; D014342:Truth Disclosure / Q000941:ethics*
D059451:Biosimilar Pharmaceuticals